Real-World Efficacy and Safety of Adalimumab Biosimilar (HS016) in Biologic-Naïve Patients with Perianal Fistulizing Crohn's Disease: A Prospective, Single-Arm, Observational Study.

Drug Des Devel Ther · 2026 · PMC13049374 · PMID 41939432

Europe PMC DOI

hedged sentence

0.0960

closest p · 1.9× alpha

0.0960

boldest claim

The sentences

showed a trendP =0.096so close (0.05 < p ≤ 0.1)

52.00% ( P =0.326), and 51.43% vs.56.00% ( P =0.726)] between patients with complex and simple PFCD. Additionally, the proportion of FCrem at both weeks 14 and 56 in patients with simple PFCD showed a trend of a higher rate than that in patients with complex PFCD (36.00%, 9/25 vs. 17.14%, 6/35) ( P =0.096).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.